Novartis Q4 Results
↓
Content
Click below to navigate
through the document
ianalumab - BAFF-R inhibitor
ianalumab - BAFF-R inhibitor
↑
Financial review
Conclusions
NCT03217422 AMBER (CVAY736B2201)
Autoimmune hepatitis
Phase 2
Indication
Phase
Patients
68
Alanine aminotransferase (ALT) normalization
VAY736
Placebo control with conversion to active VAY736
Appendix
Innovation: Pipeline overview
Financial performance
Innovation: Clinical trials
Cardiovascular, Renal
and Metabolic
> Immunology
Neuroscience
Oncology
Other
Global Health
Abbreviations
Primary
Outcome
Measures
Arms
Intervention
Target Patients
Readout
Milestone(s)
Publication
2024
TBD
Autoimmune hepatitis patients with incomplete response or intolerant to standard
treatment of care
NCT05126277 SIRIUS-LN (CVAY736K12301)
Indication
Phase
Patients
Primary Outcome
Measures
Arms
Intervention
Target Patients
Readout
Milestone(s)
Publication
Lupus Nephritis
Phase 3
420
Frequency and percentage of participants achieving complete renal response (CRR)
[ Time Frame: week 72]
Arm 1: Experimental - ianalumab s.c. q4w in addition to standard of care (SoC)
Arm 2: Experiemental - ianalumab s.c. q12w in addition to SoC
Arm 3: Placebo comparator - Placebo s.c. q4w in addition to SoC
Patients with active Lupus Nephritis
Primary 2027
TBD
Company overview
References
□ NOVARTIS | Reimagining Medicine.
Novartis Q4 Results | January 31, 2024
59View entire presentation